Entecavir hydrate

Catalog No. A11216

Entecavir hydrate，一个新的脱氧鸟嘌呤核苷类似物，是乙肝病毒复制的选择性抑制剂。

Product Citations

Masaaki Toyama, .et al. Novel Neplanocin A Derivatives as Selective Inhibitors of Hepatitis B Virus with a Unique Mechanism of Action, Antimicrob Agents Chemother, 2022, Jun 21;66(6) PMID: 35604213
Toyama M, .et al. Pyrimidotriazine derivatives as selective inhibitors of HBV capsid assembly, Virus Res, 2019, Oct 2;271:197677 PMID: 31376401
Kazumoto Murata, .et al. Induction of IFN-λ3 as an additional effect of nucleotide, not nucleoside, analogues: a new potential target for HBV infection, Gut, 2018, Feb; 67(2): 362-371 PMID: 27789659
Jianfei L, .et al. The Ca2+/CaMKK2 axis mediates the telbivudine induced upregulation of creatine kinase: Implications for mechanism of antiviral nucleoside analogs' side effect, Biochem Pharmacol, 2017, Dec 15;146:224-232 PMID: 29038020

Technical details

Catalog Num	A11216
M. Wt	295.3
Formula	C12H15N5O3.H2O
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	209216-23-9, 142217-69-4
Synonyms	ETV, Baraclude
SMILES	C=C1[C@@H]([C@H](CC1N2C=NC3=C2NC(=NC3=O)N)O)CO.O

Biological Activity

Entecavir hydrate，一个新的脱氧鸟嘌呤核苷类似物，是乙肝病毒复制的选择性抑制剂。

Targets

Reverse Transcriptase

Solubility *

In vitro	DMSO	52 mg/mL (176.09 mM)
	Water	Insoluble
	Ethanol	Insoluble
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	33.86 mL	169.32 mL	338.64 mL
0.5 mM	6.77 mL	33.86 mL	67.73 mL
1 mM	3.39 mL	16.93 mL	33.86 mL
5 mM	0.68 mL	3.39 mL	6.77 mL

*The above data is based on the productmolecular weight 295.3. Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.